Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.

Background: Dogs suffer from spontaneous tumors which may be amenable to therapies developed for human cancer patients, and dogs may serve as large-animal cancer models. A non-pathogenic Semliki Forest virus vector VA7-EGFP previously showed promise in targeting human tumor xenografts in mice, but the oncolytic capacity of the virus in canine cancer cells and the safety of the virus in higher mammals such as dogs, are not known. We therefore assessed the oncolytic potency of VA7-EGFP against canine cancer cells by infectivity and viability assays in two dog solid tumor cell lines.

Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells.

Vaccinia virus is a large, enveloped virus of the poxvirus family. It has broad tropism and typically virus replication culminates in accumulation and lytic release of intracellular mature virus (IMV), the most abundant form of infectious virus, as well as release by budding of extracellular enveloped virus (EEV). Vaccinia viruses have been modified to replicate selectively in cancer cells and clinically tested as oncolytic agents.

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles.

We evaluated adverse events, biodistribution and shedding of oncolytic vaccinia virus encoding CD40 ligand in two Beagles, in preparation for a phase 1 trial in canine cancer patients. Dog 1 received one dose of vaccinia virus and was euthanized 24 hours afterwards, while dog 2 received virus four times once weekly and was euthanized 7 days after that. Dogs were monitored for adverse events and underwent a detailed postmortem examination.

A nonhealing ulcerative skin lesion associated with Trichinella nativa infection in a cat.

Trichinella spp. can infect various domestic and wild species, including companion animals. Infection occurs because of the ingestion of raw meat (e.

Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs.

Objective: To characterize oral bioavailability and pharmacokinetic disposition of etoposide when the IV formulation was administered orally to dogs.

Animals: 8 tumor-bearing dogs.

Procedures: An open-label, single-dose, 2-way crossover study was conducted.

Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma.

Background: The optimal treatment after inducing complete remission (CR) in dogs with lymphoma has not been established.

Hypothesis: After inducing CR with L-asparaginase, vincristine, cyclophosphamide, doxorubicin, prednisone (L-CHOP); consolidation with either half-body radiation therapy (HBRT); or lomustine (CCNU) and mechlorethamine, vincristine, procarbazine, prednisone (MOPP) would improve first remission duration compared with continuing a CHOP-based protocol for an additional 4 months.

Animals: Dogs with stage III-V lymphoma.

Microalbuminuria is not associated with cisplatin-induced azotemia in dogs.

Background: Cisplatin is an effective antineoplastic agent but its use is limited by renal toxicity. Microalbuminuria is a marker of renal damage and might be an indicator of cisplatin-induced azotemia.

Null Hypothesis: Microalbuminuria is not associated with azotemia in dogs treated with cisplatin.